Gathering of industry-leading projects
Roche, one of the Fortune 500 enterprises, set up its first manufacturing facility in SIP in 2015, and since then has expanded its investment in the industrial park for several times, which has led to the recent establishment of the Asia-Pacific R&D center and the introduction of several advanced production lines and projects to SIP. Following that, a cluster of over 100 in-vitro diagnosis (IVD) products enterprises have formed in SIP.
SIP has provided great support for Roche’s projects, including helping it acquire raw materials and go through the administrative process for product registration. Now, Roche’s development in SIP has become an epitome of SIP’s efforts to foster a world-leading medical device industry chain.
In addition to Roche, SIP has attracted many world-famous companies. Olympus, a Japanese medical equipment maker, set up a medical device manufacturing base in SIP last year, manufacturing its staple products outside Japan for the first time.
B.Braun Medical Inc, a German company which provides innovative medical products and services to the healthcare industry, has created a comprehensive base in SIP for R&D, high-end manufacturing, services and training.
Santen Pharmaceutical’s new manufacturing facility in SIP has been completed. With 17 bottling lines and 10 packaging lines, it will be able to make at least 840 million eye drops each year after it reaches the designed capacity.
Dutch tech company Philips, German optical systems and optoelectronics manufacturer ZEISS and other multinationals have continuously expanded their investments in SIP, and their projects have facilitated local industrial development.
Growth of innovative projects
CH Biomedical, an SIP-headquartered medical technology company, developed China’s first artificial heart which incorporates magnetic levitation technology to pump blood and prevent thrombus.
SIP has made great efforts to bolster businesses engaged in developing innovative products. So far, 29 innovative medical devices developed in SIP have entered the country’s “Green Channel”, a special review and approval procedure designed to facilitate registration and marketing of innovative medical products, and 16 have received the marketing approval.
Development of the industry chain
SIP lays emphasis on three industries to develop the medical device industry chain, namely the industries of IVD, implantable and interventional devices, and imaging and therapeutic equipment. It also gives great support to the development of biological materials for medical uses and integration of AI technology with medical devices.
In spring, SIP saw a number of new medical device projects. The China Headquarters and in-vivo interventional cardiac support systems factory of LifeShield Medical, a multinational medical device company formed under Chinese-German cooperation, were opened, and Bio-Rad, one of the top five life science companies in the world, inaugurated an R&D center to develop resin microspheres and related products.
SIP is implementing a three-year plan to accelerate the improvement of the medical device industry chain and enhance the core competitiveness of the industry.
